Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05633602 |
|---|---|
| Brief Title: | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study |
| First Submitted : | November 21, 2022 |
| First Submitted that Met QC Criteria : | November 21, 2022 |
| First Posted : | December 1, 2022 |
| Last Update Submitted that Met QC Criteria : | February 6, 2024 |
| Last Update Posted : | February 8, 2024 |